Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality

Teresa K. Chen; Michelle M. Estrella; Lawrence J. Appel; Josef Coresh; Shengyuan Luo; Wassim Obeid; Chirag R. Parikh; Morgan E. Grams

doi:10.1093/ndt/gfaa260

Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality

Teresa K. Chen, Michelle M. Estrella, Lawrence J. Appel, Josef Coresh, Shengyuan Luo, Wassim Obeid, Chirag R. Parikh, Morgan E. Grams

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	561-563
Number of pages	3
Journal	Nephrology Dialysis Transplantation
Volume	36
Issue number	3
DOIs	https://doi.org/10.1093/ndt/gfaa260
State	Published - Mar 1 2021

ASJC Scopus subject areas

Nephrology
Transplantation

Access to Document

10.1093/ndt/gfaa260

Cite this

@article{f02d7669c9224204abf8f6f782e9a0d1,

title = "Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality",

author = "Chen, {Teresa K.} and Estrella, {Michelle M.} and Appel, {Lawrence J.} and Josef Coresh and Shengyuan Luo and Wassim Obeid and Parikh, {Chirag R.} and Grams, {Morgan E.}",

note = "Funding Information: T.K.C. is supported by a George M. O-Brien Center for Kidney Research Pilot and Feasibility Grant from Yale University (under award no. NIH/NIDDK P30DK079310) and NIH/NIDDK K08DK117068. Biomarkers were measured by the Translational Research Core of the George M. O-Brien Kidney Center at Yale University. M.E.G. and S.L. are supported by NIH/NIDDK R01DK108803. C.R.P. is supported by NIH/NIDDK U01DK106962. The AASK was conducted by the AASK investigators and supported by the NIDDK. The samples from the AASK trial reported here were supplied by the NIDDK Central Repositories via X01DK118497. The AASK trial and cohort were supported by institutional grants from the NIH and NIDDK (M01 RR-00080, M01 RR-00071, M0100032, P20-RR11145, M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, DK 2818-02, DK057867 and DK048689) and the following pharmaceutical companies (King Pharmaceuticals, Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia and Upjohn).",

year = "2021",

month = mar,

day = "1",

doi = "10.1093/ndt/gfaa260",

language = "English (US)",

volume = "36",

pages = "561--563",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality

AU - Chen, Teresa K.

AU - Estrella, Michelle M.

AU - Appel, Lawrence J.

AU - Coresh, Josef

AU - Luo, Shengyuan

AU - Obeid, Wassim

AU - Parikh, Chirag R.

AU - Grams, Morgan E.

N1 - Funding Information: T.K.C. is supported by a George M. O-Brien Center for Kidney Research Pilot and Feasibility Grant from Yale University (under award no. NIH/NIDDK P30DK079310) and NIH/NIDDK K08DK117068. Biomarkers were measured by the Translational Research Core of the George M. O-Brien Kidney Center at Yale University. M.E.G. and S.L. are supported by NIH/NIDDK R01DK108803. C.R.P. is supported by NIH/NIDDK U01DK106962. The AASK was conducted by the AASK investigators and supported by the NIDDK. The samples from the AASK trial reported here were supplied by the NIDDK Central Repositories via X01DK118497. The AASK trial and cohort were supported by institutional grants from the NIH and NIDDK (M01 RR-00080, M01 RR-00071, M0100032, P20-RR11145, M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, DK 2818-02, DK057867 and DK048689) and the following pharmaceutical companies (King Pharmaceuticals, Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia and Upjohn).

PY - 2021/3/1

Y1 - 2021/3/1

UR - http://www.scopus.com/inward/record.url?scp=85102214491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102214491&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfaa260

DO - 10.1093/ndt/gfaa260

M3 - Letter

C2 - 33156902

AN - SCOPUS:85102214491

SN - 0931-0509

VL - 36

SP - 561

EP - 563

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 3

ER -

Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this